Proscia

Proscia develops Concentriq, a pathology AI platform for case review, AI image analysis, ordering, reporting and storage of digital slides. The Concentriq portfolio has distinct configurations: Concentriq AP-Dx is cleared for primary clinical diagnosis, while Concentriq AP and LS are for research use only.

The customers are biopharmaceutical organizations and diagnostic laboratories. The website states that Proscia is trusted by 16 of the top 20 pharmaceutical companies and more than 4,000 hospitals and clinics globally. It does not describe its pricing or revenue model.

Proscia was founded in 2014 and is headquartered in Philadelphia, Pennsylvania, US. On October 13, 2026, Agilent Technologies announced a definitive agreement to acquire Proscia in an all-cash transaction valued at $240 million at closing, plus up to an additional $30 million based on future performance milestones. Open roles listed on the site include implementation engineers (Philadelphia and Dublin, Ireland), software, reliability and information security engineering, and marketing positions.

Product: Concentriq, a digital pathology platform with AI image analysis, case review, structured reporting and LIS integration, sold in research-use and clinical configurations.